nadifloxacin has been researched along with erythromycin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bojar, RA; Cunliffe, WJ; Hittel, N; Holland, KT | 1 |
| Hayashi, K; Mitsuyama, J; Yamakawa, T | 1 |
| Akar, A; Erbil, H; Ozmen, I; Tunca, M | 1 |
2 trial(s) available for nadifloxacin and erythromycin
| Article | Year |
|---|---|
Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin.
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolizines; Skin | 1995 |
Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Bacterial Agents; Erythromycin; Female; Fluoroquinolones; Humans; Male; Quinolizines; Turkey; Young Adult | 2010 |
1 other study(ies) available for nadifloxacin and erythromycin
| Article | Year |
|---|---|
In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Topics: Animals; Anti-Infective Agents; Clindamycin; Colony Count, Microbial; DNA Topoisomerase IV; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gene Frequency; Genes, Bacterial; Gentamicins; Levofloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mutation; Ofloxacin; Quinolines; Quinolizines; Staphylococcal Skin Infections; Staphylococcus aureus; Staphylococcus epidermidis; Topoisomerase II Inhibitors | 2002 |